University technology transfer offices see a steady flow of invention disclosures and have limited staff and funding to move them toward the market. AUTM's annual licensing survey tracks the output of that work across institutions, including disclosures, licenses, startups and licensing income, but the question inside an office is more immediate: which technologies deserve active commercialization effort, which fit better with an industry licensee, and which should stay in the portfolio without active development?
Most offices assess intellectual property strength and technical novelty carefully. The factors that often decide whether a medical technology reaches patients, such as the regulatory pathway, reimbursement, clinical adoption and manufacturability, can get less structured attention. A consistent scorecard helps close that gap.
What TTOs Typically Assess, and What to Add
Many TTO evaluation processes focus on three core dimensions:
- IP strength: patent scope, potential for broader claims and freedom to operate
- Technical novelty: how the invention differs from existing solutions
- Investigator credentials: whether the researcher is a recognized expert in the field
These are essential screening criteria, but they leave out factors that often decide market adoption:
- Regulatory pathway: is the device likely to need a 510(k), a De Novo request or a PMA, and does the clinical evidence exist or have to be generated? FDA's review goal for a 510(k) is 90 FDA days, but the time and cost to prepare a submission, and any clinical work behind it, vary widely by pathway; see De Novo vs 510(k).
- Reimbursement: will Medicare, commercial payers or hospitals pay for it, through which codes and at what price? See the reimbursement question.
- Clinical adoption: will clinicians use it, what switching costs and workflow changes does it require, and is it a clear need or a nice-to-have? See the clinical adoption gap.
- Manufacturing readiness: can it be made outside a research lab, at what cost and with what supply chain? See our manufacturing due diligence questions.
Offices that add these factors to IP and novelty can make better-grounded decisions about where to invest their effort.
Building a Commercialization Scorecard
A scorecard does not need to be elaborate. Its value comes from applying the same questions to every technology the office is considering for active development, so decisions can be compared and explained:
- Regulatory: likely pathway, precedent devices and the evidence still needed
- Clinical: the unmet need, the evidence to date and what adoption would require
- IP: claim scope, freedom-to-operate questions and remaining patent life
- Reimbursement: coding, coverage and payment prospects
- Commercial: the realistic licensee or buyer, and the size of the indicated market
- Manufacturing: whether the technology can be made at scale and at a viable cost
Recorded consistently, those answers support three kinds of decisions: which technologies to prioritize for startup formation or incubator support, which to market to industry licensees with the scale and regulatory experience to develop them, and which to hold without active development.
Why a Consistent Framework Helps
1. Resource Allocation
Commercialization staff and discretionary funding are limited. A consistent framework makes it easier to explain why one technology receives support and another does not, and to revisit those calls as the evidence changes.
2. Reporting to University Leadership
University leadership and advisory boards want evidence that commercialization resources are well used. Showing where each technology stands on the record, with sources attached, is more persuasive than a general sense that something looks promising.
3. Licensee and Investor Conversations
Licensees and investors will ask about regulatory, reimbursement and manufacturing assumptions. An office that has already documented the record on those questions can answer them directly. That does not guarantee a deal, but it makes the conversation more concrete.
Where Outside Review Fits
For technologies that warrant a deeper look, outside review can add clinical and engineering perspective. A Vantage TTO Report ($7,500) reads one university-held asset or spinout across eight domains (regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive position), with claims cited to their sources; it is reviewed by a physician and a biomedical engineer, delivered within 48 hours of a complete intake and followed by a 30-minute debrief. It is a read of one technology, not a ranking of the portfolio. Offices that review many disclosures can set up a TTO Program ($45,000–$75,000 a year, scoped on a call), and the automated $5,000 Quick Screen is available for screening many disclosures quickly.
Implementation: Fitting the Scorecard into TTO Workflow
A scorecard supports TTO judgment rather than replacing it. A workable sequence:
- Intake: screen new disclosures for patentability and novelty.
- Selection: at a regular interval, choose the technologies under consideration for active development, for example those with recent patent filings, strong IP positions and inventors engaged in commercialization.
- Assessment: apply the scorecard questions, internally or with outside review for the technologies that need it.
- Decision: use the results to direct startup support, licensee outreach or passive portfolio status.
- Communication: share the documented record with licensees and investors when marketing a technology or introducing a spinout.
The Bottom Line for TTO Directors
Technology transfer offices face pressure from policymakers, university leadership and inventors to show results, and licensing volume alone is an incomplete measure. A consistent way to assess commercial viability, covering regulatory, clinical, reimbursement and manufacturing questions alongside IP and novelty, helps an office direct limited resources to the technologies with the clearest path to patients.
References
Need a Custom Analysis?
Vantage full reports assemble the public record on a company, cite factual claims to their sources, and are reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME. Start with a free 20-minute call.